Cargando…

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts

BACKGROUND: One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor hemorr...

Descripción completa

Detalles Bibliográficos
Autores principales: Milanović, Dušan, Braun, Friederike, Weber, Wolfgang, Grosu, Anca Ligia, Behe, Martin, Niedermann, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476988/
https://www.ncbi.nlm.nih.gov/pubmed/22695475
http://dx.doi.org/10.1186/1471-2407-12-242
_version_ 1782247150928789504
author Milanović, Dušan
Braun, Friederike
Weber, Wolfgang
Grosu, Anca Ligia
Behe, Martin
Niedermann, Gabriele
author_facet Milanović, Dušan
Braun, Friederike
Weber, Wolfgang
Grosu, Anca Ligia
Behe, Martin
Niedermann, Gabriele
author_sort Milanović, Dušan
collection PubMed
description BACKGROUND: One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor hemorrhagic necrosis. Its selective antivascular effect is mediated by intratumoral induction of several cytokines including tumor necrosis factor-α (TNF-α), granulocyte-colony-stimulating factor (G-CSF), interleukin 6 (IL-6) and macrophage inflammatory protein 1α (MIP-1α). Preclinical studies have demonstrated that ASA404 acts synergistically with taxanes. In this study, we investigated if treatment of mice bearing U251 human glioblastoma xenografts with ASA404 and taxol may be synergistic. Therapy response was evaluated by measuring changes in tumor size and metabolic activity using (18)F-FDG PET (Fluorodeoxyglucose - positron emision tomography) imaging. METHODS: U251 cells were inoculated s.c. in the right hind limb of NMRI-Foxn1(nu) athymic female nude mice. Animals were randomly assigned into 4 groups (7–9 animals/group) for treatment: control, taxol, ASA404, and ASA404 plus taxol. The animals received either a single dose of taxol (10 mg/kg), ASA404 (27.5 mg/kg), or taxol (10 mg/kg) plus ASA404 (27.5 mg/kg) administered i.p.; ASA404 was administred 24 h after the treatment with taxol. 4 and 24 h after treatment with ASA404 (28 and 48 h hours after treatment with taxol) (18) F-FDG PET scans were performed. RESULTS: The treatment with taxol did not affect the tumor growth in comparison to untreated controls. The treatment of animals with single dose ASA404 alone or in combination with taxol caused a significant delay in tumor growth. The combined treatment did not decrease the growth of the xenografts significantly more than ASA404 alone, but early changes in tumor (18) F-FDG uptake preceded subsequent growth inhibition. The tumor weights, which were determined at the end of treatment, were lower in case of combined treatment. CONCLUSIONS: The treatment with ASA404 alone or in combination with taxol showed antitumoral effects in our glioblastoma model probably through destruction of blood vessels. The implications for the anticancer effect of this compound warrant further preclinical studies. (18)F-FDG PET appears to be a promising tool to monitor treatment with ASA404 early in the course of therapy.
format Online
Article
Text
id pubmed-3476988
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34769882012-10-23 The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts Milanović, Dušan Braun, Friederike Weber, Wolfgang Grosu, Anca Ligia Behe, Martin Niedermann, Gabriele BMC Cancer Research Article BACKGROUND: One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor hemorrhagic necrosis. Its selective antivascular effect is mediated by intratumoral induction of several cytokines including tumor necrosis factor-α (TNF-α), granulocyte-colony-stimulating factor (G-CSF), interleukin 6 (IL-6) and macrophage inflammatory protein 1α (MIP-1α). Preclinical studies have demonstrated that ASA404 acts synergistically with taxanes. In this study, we investigated if treatment of mice bearing U251 human glioblastoma xenografts with ASA404 and taxol may be synergistic. Therapy response was evaluated by measuring changes in tumor size and metabolic activity using (18)F-FDG PET (Fluorodeoxyglucose - positron emision tomography) imaging. METHODS: U251 cells were inoculated s.c. in the right hind limb of NMRI-Foxn1(nu) athymic female nude mice. Animals were randomly assigned into 4 groups (7–9 animals/group) for treatment: control, taxol, ASA404, and ASA404 plus taxol. The animals received either a single dose of taxol (10 mg/kg), ASA404 (27.5 mg/kg), or taxol (10 mg/kg) plus ASA404 (27.5 mg/kg) administered i.p.; ASA404 was administred 24 h after the treatment with taxol. 4 and 24 h after treatment with ASA404 (28 and 48 h hours after treatment with taxol) (18) F-FDG PET scans were performed. RESULTS: The treatment with taxol did not affect the tumor growth in comparison to untreated controls. The treatment of animals with single dose ASA404 alone or in combination with taxol caused a significant delay in tumor growth. The combined treatment did not decrease the growth of the xenografts significantly more than ASA404 alone, but early changes in tumor (18) F-FDG uptake preceded subsequent growth inhibition. The tumor weights, which were determined at the end of treatment, were lower in case of combined treatment. CONCLUSIONS: The treatment with ASA404 alone or in combination with taxol showed antitumoral effects in our glioblastoma model probably through destruction of blood vessels. The implications for the anticancer effect of this compound warrant further preclinical studies. (18)F-FDG PET appears to be a promising tool to monitor treatment with ASA404 early in the course of therapy. BioMed Central 2012-06-13 /pmc/articles/PMC3476988/ /pubmed/22695475 http://dx.doi.org/10.1186/1471-2407-12-242 Text en Copyright ©2012 Milanović et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Milanović, Dušan
Braun, Friederike
Weber, Wolfgang
Grosu, Anca Ligia
Behe, Martin
Niedermann, Gabriele
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title_full The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title_fullStr The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title_full_unstemmed The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title_short The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
title_sort influence of the combined treatment with vadimezan (asa404) and taxol on the growth of u251 glioblastoma xenografts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476988/
https://www.ncbi.nlm.nih.gov/pubmed/22695475
http://dx.doi.org/10.1186/1471-2407-12-242
work_keys_str_mv AT milanovicdusan theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT braunfriederike theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT weberwolfgang theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT grosuancaligia theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT behemartin theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT niedermanngabriele theinfluenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT milanovicdusan influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT braunfriederike influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT weberwolfgang influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT grosuancaligia influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT behemartin influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts
AT niedermanngabriele influenceofthecombinedtreatmentwithvadimezanasa404andtaxolonthegrowthofu251glioblastomaxenografts